BeiGene, Ltd. (NASDAQ:BGNE) Insider Sells $417,548.18 in Stock

BeiGene, Ltd. (NASDAQ:BGNEGet Rating) insider Xiaodong Wang sold 1,987 shares of the business’s stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $210.14, for a total transaction of $417,548.18. Following the transaction, the insider now owns 5,629,556 shares of the company’s stock, valued at $1,182,994,897.84. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

BeiGene Stock Performance

BeiGene stock opened at $203.13 on Friday. The company has a quick ratio of 3.87, a current ratio of 4.07 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $21.06 billion, a PE ratio of -9.51 and a beta of 0.82. The firm has a fifty day simple moving average of $162.82 and a two-hundred day simple moving average of $162.44. BeiGene, Ltd. has a twelve month low of $118.18 and a twelve month high of $369.93.

Analysts Set New Price Targets

Several research analysts recently issued reports on BGNE shares. Cowen upped their target price on shares of BeiGene from $200.00 to $213.00 in a research report on Thursday, November 10th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $296.00 target price on shares of BeiGene in a research report on Tuesday, August 9th. SVB Leerink upped their target price on shares of BeiGene from $200.00 to $210.00 and gave the stock an “outperform” rating in a research report on Thursday, November 10th. Guggenheim upped their target price on shares of BeiGene to $210.00 in a research report on Tuesday, November 15th. Finally, Morgan Stanley upped their target price on shares of BeiGene from $290.00 to $295.00 and gave the stock an “overweight” rating in a research report on Thursday, October 13th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $239.50.

Institutional Trading of BeiGene

Hedge funds have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC bought a new stake in BeiGene in the second quarter worth $65,000. China Universal Asset Management Co. Ltd. bought a new position in shares of BeiGene during the third quarter valued at about $61,000. Rockefeller Capital Management L.P. raised its stake in shares of BeiGene by 8.3% during the third quarter. Rockefeller Capital Management L.P. now owns 885 shares of the company’s stock valued at $119,000 after acquiring an additional 68 shares during the last quarter. Whittier Trust Co. of Nevada Inc. bought a new position in shares of BeiGene during the third quarter valued at about $165,000. Finally, Advisors Asset Management Inc. raised its stake in shares of BeiGene by 26.7% during the first quarter. Advisors Asset Management Inc. now owns 1,244 shares of the company’s stock valued at $235,000 after acquiring an additional 262 shares during the last quarter. 51.77% of the stock is owned by institutional investors.

BeiGene Company Profile

(Get Rating)

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Featured Stories

Insider Buying and Selling by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.